Heron Therapeutics Forecasts Q4 Revenue of $40.5 Million, Consensus $39.83 Million
“We are encouraged by growth in the fourth quarter of 2025, driven in particular by the momentum of our critical care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are very pleased with the continued progress made in all aspects of our business over the past year.”…